/
We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Our Portfolio Our portfolio is principally focused on our lead product candidate, Niyad (nafamostat mesylate), for use as a regional anticoagulant during continuous renal replacement therapy, or CRRT.
The business is unprofitable at the operating level (-48157.14% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Negative free cash flow of -$11M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$1K
Net Income (TTM)
-$14M
▼ -9.9% YoY
Op. Margin
-1451600.00%
ROIC
-74.81%
▲ +23.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$11M
▲ +10.4% YoY
Op. Cash Flow (TTM)
-$11M
▲ +10.4% YoY
Net Debt
-$21M
Net Cash Position
Cash & Equiv.
$21M
5Y CAGR: -65.1%
Continue Research